In November 2015, the TRIPS Council decided to extend exemptions from the pharmaceutical patent and undisclosed information protection for least developed countries until 1 January 2033 or until 1 January 2033, when they are no longer members of the least developed countries, the date when these countries are no longer members. They are also exempt from the otherwise existing obligations to accept the filing of patent applications and to grant exclusive marketing rights during the transitional period. such as the general provisions and fundamental principles of the multilateral trading system for the international application of intellectual property The exclusive rights to be granted by the product patent are the rights that must be manufactured, used, sold, sold and imported for these purposes. The protection of process patents must be entitled not only to the use of the procedure, but also to the products obtained directly by the process. Patent holders also have the right to transfer or transfer the patent to the right and to enter into licensing agreements (Article 28). Among these agreements, the ip rights trade (TRIPS) aspects are expected to have the greatest impact on the pharmaceutical sector and access to medicines. The TRIPS agreement has been in force since 1995 and is the most comprehensive multilateral IP agreement to date. The TRIPS agreement introduced global minimum standards for the protection and enforcement of almost all forms of intellectual property rights (IPRs), including patent rights. International agreements prior to TRIPS did not contain minimum patent standards. At the time negotiations began, more than 40 countries around the world did not grant patent protection for pharmaceuticals.
The TRIPS agreement now requires all WTO members, with a few exceptions, to adapt their legislation to minimum standards of intellectual property protection. In addition, the TRIPS agreement introduced detailed obligations to respect intellectual property rights. Where the signs are not inherently likely to distinguish the products or services in question, Member States may require, as an additional condition of registration as a trademark, that the distinctiveness has been acquired through use. Members are free to decide whether to allow the recording of signs that are not visually noticeable (. B for example, sound or olfactory traces). Since the TRIPS agreement came into force, it has been criticized by developing countries, scientists and non-governmental organizations. While some of this criticism is generally opposed to the WTO, many proponents of trade liberalization also view TRIPS policy as a bad policy. The effects of the concentration of WEALTH of TRIPS (money from people in developing countries for copyright and patent holders in industrialized countries) and the imposition of artificial shortages on citizens of countries that would otherwise have had weaker intellectual property laws are common bases for such criticisms. Other critics have focused on the inability of trips trips to accelerate the flow of investment and technology to low-income countries, a benefit that WTO members achieved prior to the creation of the agreement. The World Bank`s statements indicate that TRIPS have clearly not accelerated investment in low-income countries, whereas they may have done so for middle-income countries.  As part of TRIPS, long periods of patent validity were examined to determine the excessive slowdown in generic drug entry and competition.